{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T03:39:40Z","timestamp":1792813180446,"version":"4.5.0"},"reference-count":118,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,12,16]],"date-time":"2021-12-16T00:00:00Z","timestamp":1639612800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>With advances in allogeneic hematopoietic stem cell transplant (allo-HCT), disease relapse has replaced transplant-related mortality as the primary cause of treatment failure for patients with acute myeloid leukemia (AML). The efficacy of allo-HCT in AML is a consequence of a graft-versus-leukemia (GVL) effect that is mediated by T lymphocytes, and unique mechanisms of immune evasion underlying post-allo-HCT AML relapses have recently been characterized. Relapsed AML following allo-HCT presents a particularly vexing clinical challenge because transplant-related toxicities, such as graft-versus-host (GVHD) and infections, increase the risk of treatment-related morbidity and mortality. In general, the prognosis of relapsed AML following allo-HCT is poor with most patients failing to achieve a subsequent remission and 2-year survival consistently &amp;lt;15%. The two factors that have been found to predict a better prognosis are a longer duration of post-transplant remission prior to relapse and a lower disease burden at the time of relapse. When considered in combination with a patient\u2019s age; co-morbidities; and performance status, these factors can help to inform the appropriate therapy for the treatment of post-transplant relapse. This review discusses the options for the treatment of post-transplant AML relapse with a focus on the options to achieve a subsequent remission and consolidation with cellular immunotherapy, such as a second transplant or donor lymphocyte infusion (DLI). While intensive reinduction therapy and less intensive approaches with hypomethylating agents have long represented the two primary options for the initial treatment of post-transplant relapse, molecularly targeted therapies and immunotherapy are emerging as potential alternative options to achieve remission. Herein, we highlight response and survival outcomes achieved specifically in the post-transplant setting using each of these approaches and discuss how some therapies may overcome the immunologic mechanisms that have been implicated in post-transplant relapse. As long-term survival in post-transplant relapse necessarily involves consolidation with cellular immunotherapy, we present data on the efficacy and toxicity of both DLI and second allo-HCT including when such therapies are integrated with reinduction. Finally, we provide our general approach to the treatment of post-transplant relapse, integrating both novel therapies and our improved understanding of the mechanisms underlying post-transplant relapse.<\/jats:p>","DOI":"10.3389\/fonc.2021.812207","type":"journal-article","created":{"date-parts":[[2021,12,16]],"date-time":"2021-12-16T05:24:13Z","timestamp":1639632253000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":40,"title":["Treatment of AML Relapse After Allo-HCT"],"prefix":"10.3389","volume":"11","author":[{"given":"Jonathan A.","family":"Webster","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leo","family":"Luznik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivana","family":"Gojo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,12,16]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-09-3724","article-title":"Age and Acute Myeloid Leukemia","volume":"107","author":"Appelbaum","year":"2006","journal-title":"Blood"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2009.813","article-title":"Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia in First Complete Remission: Systematic Review and Meta-Analysis of Prospective Clinical Trials","volume":"301","author":"Koreth","year":"2009","journal-title":"JAMA"},{"key":"B3","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtct.2021.02.031","article-title":"Myeloablative Versus Reduced-Intensity Conditioning for Hematopoietic Cell Transplantation in Acute Myelogenous Leukemia and Myelodysplastic Syndromes-Long-Term Follow-Up of the BMT CTN 0901 Clinical Trial","volume":"27","author":"Scott","year":"2021","journal-title":"Transplant Cell Ther"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2015.121","article-title":"Conditioning Intensity in Middle-Aged Patients With AML in First CR: No Advantage for Myeloablative Regimens Irrespective of the Risk Group-an Observational Analysis by the Acute Leukemia Working Party of the EBMT","volume":"50","author":"Passweg","year":"2015","journal-title":"Bone Marrow Transplant"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.20.9692","article-title":"Reduced Intensity Conditioning Compared With Myeloablative Conditioning Using Unrelated Donor Transplants in Patients With Acute Myeloid Leukemia","volume":"27","author":"Ringden","year":"2009","journal-title":"J Clin Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-018-0171-z","article-title":"Epidemiology and Biology of Relapse After Stem Cell Transplantation","volume":"53","author":"Horowitz","year":"2018","journal-title":"Bone Marrow Transplant"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-08-375840","article-title":"Treatment, Risk Factors, and Outcome of Adults With Relapsed AML After Reduced Intensity Conditioning for Allogeneic Stem Cell Transplantation","volume":"119","author":"Schmid","year":"2012","journal-title":"Blood"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2014.332","article-title":"Comparative Therapeutic Value of Post-Remission Approaches in Patients With Acute Myeloid Leukemia Aged 40-60 Years","volume":"29","author":"Cornelissen","year":"2015","journal-title":"Leukemia"},{"key":"B9","unstructured":"Number of HCTs Performed in the United States and Reported to CIBMTR - Cell Source and Donor Category by Donor Type and Year2019"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2014.11.007","article-title":"Survival of Patients With Acute Myeloid Leukemia Relapsing After Allogeneic Hematopoietic Cell Transplantation: A Center for International Blood and Marrow Transplant Research Study","volume":"21","author":"Bejanyan","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V75.3.555.555","article-title":"Graft-Versus-Leukemia Reactions After Bone Marrow Transplantation","volume":"75","author":"Horowitz","year":"1990","journal-title":"Blood"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197905103001902","article-title":"Antileukemic Effect of Graft-Versus-Host Disease in Human Recipients of Allogeneic-Marrow Grafts","volume":"300","author":"Weiden","year":"1979","journal-title":"N Engl J Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V86.5.2041.bloodjournal8652041","article-title":"Graft-Versus-Leukemia Effect of Donor Lymphocyte Transfusions in Marrow Grafted Patients","volume":"86","author":"Kolb","year":"1995","journal-title":"Blood"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.11.6053","article-title":"Donor Lymphocyte Infusion in the Treatment of First Hematological Relapse After Allogeneic Stem-Cell Transplantation in Adults With Acute Myeloid Leukemia: A Retrospective Risk Factors Analysis and Comparison With Other Strategies by the EBMT Acute Leukemia Working Party","volume":"25","author":"Schmid","year":"2007","journal-title":"J Clin Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1808777","article-title":"Immune Escape of Relapsed AML Cells After Allogeneic Transplantation","volume":"379","author":"Christopher","year":"2018","journal-title":"N Engl J Med"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-019-0400-z","article-title":"Immune Signature Drives Leukemia Escape and Relapse After Hematopoietic Cell Transplantation","volume":"25","author":"Toffalori","year":"2019","journal-title":"Nat Med"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0811036","article-title":"Loss of Mismatched HLA in Leukemia After Stem-Cell Transplantation","volume":"361","author":"Vago","year":"2009","journal-title":"N Engl J Med"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2016.144","article-title":"Loss of the Mismatched Human Leukocyte Antigen Haplotype in Two Acute Myelogenous Leukemia Relapses After Haploidentical Bone Marrow Transplantation With Post-Transplantation Cyclophosphamide","volume":"30","author":"McCurdy","year":"2016","journal-title":"Leukemia"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-08871-1","article-title":"Bone Marrow Central Memory and Memory Stem T-Cell Exhaustion in AML Patients Relapsing After HSCT","volume":"10","author":"Noviello","year":"2019","journal-title":"Nat Commun"},{"key":"B20","doi-asserted-by":"publisher","first-page":"3742","DOI":"10.1182\/blood.V124.21.3742.3742","article-title":"A Randomized Phase II Trial of Three Novel Regimens for Relapsed\/ Refractory Acute Myeloid Leukemia (AML) Demonstrates Encouraging Results With a Flavopiridol-Based Regimen: Results of Eastern Cooperative Oncology Group (ECOG) Trial E1906","volume":"124","author":"Litzow","year":"2014","journal-title":"Blood"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00201-6","article-title":"Vosaroxin Plus Cytarabine Versus Placebo Plus Cytarabine in Patients With First Relapsed or Refractory Acute Myeloid Leukaemia (VALOR): A Randomised, Controlled, Double-Blind, Multinational, Phase 3 Study","volume":"16","author":"Ravandi","year":"2015","journal-title":"Lancet Oncol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.21545","article-title":"Salvage Therapy for Acute Myeloid Leukemia With Fludarabine, Cytarabine, and Idarubicin With or Without Gemtuzumab Ozogamicin and With Concurrent or Sequential G-CSF","volume":"84","author":"Martin","year":"2009","journal-title":"Am J Hematol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/S0145-2126(99)00087-9","article-title":"A Phase III Comparison of High Dose ARA-C (HIDAC) Versus HIDAC Plus Mitoxantrone in the Treatment of First Relapsed or Refractory Acute Myeloid Leukemia Southwest Oncology Group Study","volume":"23","author":"Karanes","year":"1999","journal-title":"Leuk Res"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-003-0624-2","article-title":"FLAG-IDA in the Treatment of Refractory\/Relapsed Acute Myeloid Leukemia: Single-Center Experience","volume":"82","author":"Pastore","year":"2003","journal-title":"Ann Hematol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1991.9.7.1210","article-title":"Mitoxantrone, Etoposide, and Intermediate-Dose Cytarabine: An Effective and Tolerable Regimen for the Treatment of Refractory Acute Myeloid Leukemia","volume":"9","author":"Amadori","year":"1991","journal-title":"J Clin Oncol"},{"key":"B26","article-title":"Mitoxantrone, Etoposide and Intermediate-Dose Ara-C (MEC): An Effective Regimen for Poor Risk Acute Myeloid Leukemia","volume":"7","author":"Spadea","year":"1993","journal-title":"Leukemia"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2007.00988.x","article-title":"Cladribine Combined With High Doses of Arabinoside Cytosine, Mitoxantrone, and G-CSF (CLAG-M) Is a Highly Effective Salvage Regimen in Patients With Refractory and Relapsed Acute Myeloid Leukemia of the Poor Risk: A Final Report of the Polish Adult Leukemia Group","volume":"80","author":"Wierzbowska","year":"2008","journal-title":"Eur J Haematol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-014-2229-3","article-title":"Salvage Therapy With ARA-C and Gemtuzumab Ozogamicin in AML Patients Relapsing After Stem Cell Transplantation","volume":"94","author":"Koren-Michowitz","year":"2015","journal-title":"Ann Hematol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2016.03.023","article-title":"Chemotherapy Versus Hypomethylating Agents for the Treatment of Relapsed Acute Myeloid Leukemia and Myelodysplastic Syndrome After Allogeneic Stem Cell Transplant","volume":"22","author":"Motabi","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2014.300","article-title":"Treatment Strategies in Patients With AML or High-Risk Myelodysplastic Syndrome Relapsed After Allo-SCT","volume":"50","author":"Sauer","year":"2015","journal-title":"Bone Marrow Transplant"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2012.741230","article-title":"Outcome of Relapse After Allogeneic Stem Cell Transplant in Patients With Acute Myeloid Leukemia","volume":"54","author":"Devillier","year":"2013","journal-title":"Leuk Lymphoma"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.20.2.405","article-title":"Prospective Trial of Chemotherapy and Donor Leukocyte Infusions for Relapse of Advanced Myeloid Malignancies After Allogeneic Stem-Cell Transplantation","volume":"20","author":"Levine","year":"2002","journal-title":"J Clin Oncol"},{"key":"B33","article-title":"A Phase III Trial of High-Dose Cytosine Arabinoside With or Without Etoposide in Relapsed and Refractory Acute Myelogenous Leukemia. A Southeastern Cancer Study Group Trial","volume":"8","author":"Vogler","year":"1994","journal-title":"Leukemia"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-01-621664","article-title":"International Phase 3 Study of Azacitidine vs Conventional Care Regimens in Older Patients With Newly Diagnosed AML With >30% Blasts","volume":"126","author":"Dombret","year":"2015","journal-title":"Blood"},{"key":"B35","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1097\/00002371-199901000-00003","article-title":"Prolonged Upregulation of the Expression of HLA Class I Antigens and Costimulatory Molecules on Melanoma Cells Treated With 5-Aza-2\u2019-Deoxycytidine (5-AZA-CdR)","volume":"22","author":"Coral","year":"1999","journal-title":"J\u00a0Immunother"},{"key":"B36","article-title":"5-Aza-2\u2019-Deoxycytidine-Induced Expression of Functional Cancer Testis Antigens in Human Renal Cell Carcinoma: Immunotherapeutic Implications","volume":"8","author":"Coral","year":"2002","journal-title":"Clin Cancer Res"},{"key":"B37","doi-asserted-by":"publisher","first-page":"e197","DOI":"10.1038\/bcj.2014.14","article-title":"5-Azacytidine Treatment Sensitizes Tumor Cells to T-Cell Mediated Cytotoxicity and Modulates NK Cells in Patients With Myeloid Malignancies","volume":"4","author":"Gang","year":"2014","journal-title":"Blood Cancer J"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0070-8","article-title":"Hypomethylating Agents in Combination With Immune Checkpoint Inhibitors in Acute Myeloid Leukemia and Myelodysplastic Syndromes","volume":"32","author":"Daver","year":"2018","journal-title":"Leukemia"},{"key":"B39","doi-asserted-by":"publisher","first-page":"e1314425","DOI":"10.1080\/2162402X.2017.1314425","article-title":"Azacytidine Prevents Experimental Xenogeneic Graft-Versus-Host Disease Without Abrogating Graft-Versus-Leukemia Effects","volume":"6","author":"Ehx","year":"2017","journal-title":"Oncoimmunol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-03-210393","article-title":"Immunomodulatory Effect of 5-Azacytidine (5-Azac): Potential Role in the Transplantation Setting","volume":"115","author":"Sanchez-Abarca","year":"2010","journal-title":"Blood"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-12-257253","article-title":"In Vivo Administration of Hypomethylating Agents Mitigate Graft-Versus-Host Disease Without Sacrificing Graft-Versus-Leukemia","volume":"116","author":"Choi","year":"2010","journal-title":"Blood"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1038\/nm915","article-title":"CD4+CD25+ Regulatory T Cells Preserve Graft-Versus-Tumor Activity While Inhibiting Graft-Versus-Host Disease After Bone Marrow Transplantation","volume":"9","author":"Edinger","year":"2003","journal-title":"Nat Med"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2010.10.008","article-title":"5-Azacytidine as Salvage Treatment in Relapsed Myeloid Tumors After Allogeneic Bone Marrow Transplantation","volume":"17","author":"Bolanos-Meade","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2011.234","article-title":"Azacitidine for Treatment of Imminent Relapse in MDS or AML Patients After Allogeneic HSCT: Results of the RELAZA Trial","volume":"26","author":"Platzbecker","year":"2012","journal-title":"Leukemia"},{"key":"B45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/10428194.2021.1948029","article-title":"A Phase II Study of Azacitidine in Combination With Granulocyte-Macrophage Colony-Stimulating Factor as Maintenance Treatment, After Allogeneic Blood or Marrow Transplantation in Patients With Poor-Risk Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)","author":"Webster","year":"2021","journal-title":"Leuk Lymphoma"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2015.09.004","article-title":"Tolerability and Clinical Activity of Post-Transplantation Azacitidine in Patients Allografted for Acute Myeloid Leukemia Treated on the RICAZA Trial","volume":"22","author":"Craddock","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2015.05.026","article-title":"Maintenance Therapy With Decitabine After Allogeneic Stem Cell Transplantation for Acute Myelogenous Leukemia and Myelodysplastic Syndrome","volume":"21","author":"Pusic","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.06.016","article-title":"CC-486 Maintenance After Stem Cell Transplantation in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes","volume":"24","author":"de Lima","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2018.1443334","article-title":"Maintenance Azacitidine After Myeloablative Allogeneic Hematopoietic Cell Transplantation for Myeloid Malignancies","volume":"59","author":"Maples","year":"2018","journal-title":"Leuk Lymphoma"},{"key":"B50","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/10428194.2020.1789630","article-title":"Conditioning Regimen Intensity and Low-Dose Azacitidine Maintenance After Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia","author":"Ali","year":"2020","journal-title":"Leuk Lymphoma"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020002544","article-title":"A Phase 3 Randomized Study of 5-Azacitidine Maintenance vs Observation After Transplant in High-Risk AML and MDS Patients","volume":"4","author":"Oran","year":"2020","journal-title":"Blood Adv"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.03277","article-title":"Effect of rhG-CSF Combined With Decitabine Prophylaxis on Relapse of Patients With High-Risk MRD-Negative AML After HSCT: An Open-Label, Multicenter, Randomized Controlled Trial","volume":"38","author":"Gao","year":"2020","journal-title":"J Clin Oncol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2015.140996","article-title":"Clinical Activity of Azacitidine in Patients Who Relapse After Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia","volume":"101","author":"Craddock","year":"2016","journal-title":"Haematologica"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2009.222","article-title":"Efficacy of a 3-Day, Low-Dose Treatment With 5-Azacytidine Followed by Donor Lymphocyte Infusions in Older Patients With Acute Myeloid Leukemia or Chronic Myelomonocytic Leukemia Relapsed After Allografting","volume":"45","author":"Lubbert","year":"2010","journal-title":"Bone Marrow Transplant"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2013.233","article-title":"Azacitidine Salvage Therapy for Relapse of Myeloid Malignancies Following Allogeneic Hematopoietic SCT","volume":"49","author":"Tessoulin","year":"2014","journal-title":"Bone Marrow Transplant"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-017-3185-5","article-title":"Treatment of Relapsed AML and MDS After Allogeneic Stem Cell Transplantation With Decitabine and DLI-A Retrospective Multicenter Analysis on Behalf of the German Cooperative Transplant Study Group","volume":"97","author":"Schroeder","year":"2018","journal-title":"Ann Hematol"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12082255","article-title":"Prediction of Response and Survival Following Treatment With Azacitidine for Relapse of Acute Myeloid Leukemia and Myelodysplastic Syndromes After Allogeneic Hematopoietic Stem Cell Transplantation","volume":"12","author":"Rautenberg","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1038\/s41418-018-0228-y","article-title":"Recipient BCL2 Inhibition and NK Cell Ablation Form Part of a Reduced Intensity Conditioning Regime That Improves Allo-Bone Marrow Transplantation Outcomes","volume":"26","author":"Jiao","year":"2019","journal-title":"Cell Death Differ"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1126\/science.1068440","article-title":"Effectiveness of Donor Natural Killer Cell Alloreactivity in Mismatched Hematopoietic Transplants","volume":"295","author":"Ruggeri","year":"2002","journal-title":"Science"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N Engl J Med"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-020-04321-x","article-title":"Treatment of Myeloid Malignancies Relapsing After Allogeneic Hematopoietic Stem Cell Transplantation With Venetoclax and Hypomethylating Agents-a Retrospective Multicenter Analysis on Behalf of the German Cooperative Transplant Study Group","volume":"100","author":"Schuler","year":"2021","journal-title":"Ann Hematol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019000930","article-title":"Invasive Fungal Infections in Acute Myeloid Leukemia Treated With Venetoclax and Hypomethylating Agents","volume":"3","author":"Aldoss","year":"2019","journal-title":"Blood Adv"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00437-z","article-title":"Salvage Use of Venetoclax-Based Therapy for Relapsed AML Post Allogeneic Hematopoietic Cell Transplantation","volume":"11","author":"Joshi","year":"2021","journal-title":"Blood Cancer J"},{"key":"B64","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1002\/ajh.23746","article-title":"Lenalidomide-Based Maintenance Therapy Reduces TNF Receptor 2 on CD4 T Cells and Enhances Immune Effector Function in Acute Myeloid Leukemia Patients","volume":"89","author":"Govindaraj","year":"2014","journal-title":"Am J Hematol"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-04-348292","article-title":"Lenalidomide Maintenance After Nonmyeloablative Allogeneic Stem Cell Transplantation in Multiple Myeloma Is Not Feasible: Results of the HOVON 76 Trial","volume":"118","author":"Kneppers","year":"2011","journal-title":"Blood"},{"key":"B66","doi-asserted-by":"publisher","first-page":"34","DOI":"10.3324\/haematol.2012.067629","article-title":"Lenalidomide Maintenance After Allogeneic HSCT Seems to Trigger Acute Graft-Versus-Host Disease in Patients With High-Risk Myelodysplastic Syndromes or Acute Myeloid Leukemia and Del(5q): Results of the LENAMAINT Trial","volume":"97","author":"Sockel","year":"2012","journal-title":"Haematologica"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.00889","article-title":"Combination Lenalidomide and Azacitidine: A Novel Salvage Therapy in Patients Who Relapse After Allogeneic Stem-Cell Transplantation for Acute Myeloid Leukemia","volume":"37","author":"Craddock","year":"2019","journal-title":"J Clin Oncol"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1301689","article-title":"Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia","volume":"368","author":"Ley","year":"2013","journal-title":"N Engl J Med"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24072","article-title":"Characteristics, Clinical Outcome, and Prognostic Significance of IDH Mutations in AML","volume":"90","author":"DiNardo","year":"2015","journal-title":"Am J Hematol"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-019-03606-0","article-title":"The Leukemia Strikes Back: A Review of Pathogenesis and Treatment of Secondary AML","volume":"98","author":"Cheung","year":"2019","journal-title":"Ann Hematol"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-10-249128","article-title":"Allogeneic Transplantation for Therapy-Related Myelodysplastic Syndrome and Acute Myeloid Leukemia","volume":"115","author":"Litzow","year":"2010","journal-title":"Blood"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2018019976","article-title":"Conditioning Intensity in Secondary AML With Prior Myelodysplastic Syndrome\/Myeloproliferative Disorders: An EBMT ALWP Study","volume":"2","author":"Sengsayadeth","year":"2018","journal-title":"Blood Adv"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1902688","article-title":"Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML","volume":"381","author":"Perl","year":"2019","journal-title":"N Engl J Med"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23924","article-title":"Phase I\/II Trial of the Combination of Midostaurin (PKC412) and 5-Azacytidine for Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome","volume":"90","author":"Strati","year":"2015","journal-title":"Am J Hematol"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-04-779405","article-title":"Enasidenib in Mutant IDH2 Relapsed or Refractory Acute Myeloid Leukemia","volume":"130","author":"Stein","year":"2017","journal-title":"Blood"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1716984","article-title":"Durable Remissions With Ivosidenib in IDH1-Mutated Relapsed or Refractory AML","volume":"378","author":"DiNardo","year":"2018","journal-title":"N Engl J Med"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2018.211615","article-title":"Sorafenib Improves Survival of FLT3-Mutated Acute Myeloid Leukemia in Relapse After Allogeneic Stem Cell Transplantation: A Report of the EBMT Acute Leukemia Working Party","volume":"104","author":"Bazarbachi","year":"2019","journal-title":"Haematologica"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2012.105","article-title":"High Activity of Sorafenib in FLT3-ITD-Positive Acute Myeloid Leukemia Synergizes With Allo-Immune Effects to Induce Sustained Responses","volume":"26","author":"Metzelder","year":"2012","journal-title":"Leukemia"},{"key":"B79","doi-asserted-by":"publisher","first-page":"e447","DOI":"10.1038\/bcj.2016.60","article-title":"An Open-Label Phase I Dose-Finding Study of APR-246 in Hematological Malignancies","volume":"6","author":"Deneberg","year":"2016","journal-title":"Blood Cancer J"},{"key":"B80","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1182\/blood-2020-134942","article-title":"Preliminary Data on a Phase 1\/2A First in Human Study of the Menin-KMT2A (MLL) Inhibitor KO-539 in Patients With Relapsed or Refractory Acute Myeloid Leukemia","volume":"136","author":"Wang","year":"2020","journal-title":"Blood"},{"key":"B81","article-title":"Syndax Announces Positive Interim Data Demonstrating Robust Clinical Activity in Phase 1 Portion of the AUGMENT-101 Trial of SNDX-5613 in Patients With Genetically-Defined Acute Leukemias","author":"Kolinski","year":"2021"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-04-1443","article-title":"BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF\/MEK\/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis","volume":"64","author":"Wilhelm","year":"2004","journal-title":"Cancer Res"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4484","article-title":"Sorafenib Promotes Graft-Versus-Leukemia Activity in Mice and Humans Through IL-15 Production in FLT3-ITD-Mutant Leukemia Cells","volume":"24","author":"Mathew","year":"2018","journal-title":"Nat Med"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-01-480228","article-title":"Phase 2 Study of Azacytidine Plus Sorafenib in Patients With Acute Myeloid Leukemia and FLT-3 Internal Tandem Duplication Mutation","volume":"121","author":"Ravandi","year":"2013","journal-title":"Blood"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1614359","article-title":"Midostaurin Plus Chemotherapy for Acute Myeloid Leukemia With a FLT3 Mutation","volume":"377","author":"Stone","year":"2017","journal-title":"N Engl J Med"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-08-869008","article-title":"Molecular Remission and Response Patterns in Patients With Mutant-IDH2 Acute Myeloid Leukemia Treated With Enasidenib","volume":"133","author":"Stein","year":"2019","journal-title":"Blood"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13912","article-title":"TP53 Mutation in Patients With High-Risk Acute Myeloid Leukaemia Treated With Allogeneic Haematopoietic Stem Cell Transplantation","volume":"172","author":"Middeke","year":"2016","journal-title":"Br J Haematol"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1038\/nm0302-282","article-title":"Restoration of the Tumor Suppressor Function to Mutant P53 by a Low-Molecular-Weight Compound","volume":"8","author":"Bykov","year":"2002","journal-title":"Nat Med"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.02341","article-title":"Eprenetapopt (APR-246) and Azacitidine in TP53-Mutant Myelodysplastic Syndromes","volume":"39","author":"Sallman","year":"2021","journal-title":"J Clin Oncol"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.02342","article-title":"Eprenetapopt Plus Azacitidine in TP53-Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Phase II Study by the Groupe Francophone Des Myelodysplasies (GFM)","volume":"39","author":"Cluzeau","year":"2021","journal-title":"J Clin Oncol"},{"key":"B91","volume-title":"Aprea Therapeutics Announces Results of Primary Endpoint From Phase 3 Trial of Eprenetapopt in TP53 Mutant Myelodysplastic Syndromes (MDS)","author":"Korbel","year":"2020"},{"key":"B92","volume-title":"Aprea Therapeutics Announces Positive Results From Phase 2 Trial of Eprenetapopt + Azacitidine for Post-Transplant Maintenance Therapy in TP53 Mutant MDS and AML","author":"Korbel","year":"2021"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2015.143","article-title":"Outcome of Allogeneic Hematopoietic Stem-Cell Transplantation for Adult Patients With AML and 11q23\/MLL Rearrangement (MLL-R AML)","volume":"29","author":"Pigneux","year":"2015","journal-title":"Leukemia"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25355","article-title":"Hematopoietic Stem Cell Transplantation for Adult Patients With Isolated NPM1 Mutated Acute Myeloid Leukemia in First Remission","volume":"94","author":"Poire","year":"2019","journal-title":"Am J Hematol"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2020.02.011","article-title":"It\u2019s All About MEis: Menin-MLL Inhibition Eradicates NPM1-Mutated and MLL-Rearranged Acute Leukemias in Mice","volume":"37","author":"Gundry","year":"2020","journal-title":"Cancer Cell"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404828","article-title":"Treatment of AML and MDS Relapsing After Reduced-Intensity Conditioning and Allogeneic Hematopoietic Stem Cell Transplantation","volume":"21","author":"Oran","year":"2007","journal-title":"Leukemia"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.72.8428","article-title":"Mobilized Peripheral Blood Stem Cells Versus Unstimulated Bone Marrow as a Graft Source for T-Cell-Replete Haploidentical Donor Transplantation Using Post-Transplant Cyclophosphamide","volume":"35","author":"Bashey","year":"2017","journal-title":"J Clin Oncol"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.09.020","article-title":"Allogeneic Peripheral Blood Stem-Cell Compared With Bone Marrow Transplantation in the Management of Hematologic Malignancies: An Individual Patient Data Meta-Analysis of Nine Randomized Trials","volume":"23","year":"2005","journal-title":"J Clin Oncol"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1701119","article-title":"Serial and Quantitative Analysis of Mixed Hematopoietic Chimerism by PCR in Patients With Acute Leukemias Allows the Prediction of Relapse After Allogeneic BMT","volume":"21","author":"Bader","year":"1998","journal-title":"Bone Marrow Transplant"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2014.12.029","article-title":"Chimerism-Based Pre-Emptive Immunotherapy With Fast Withdrawal of Immunosuppression and Donor Lymphocyte Infusions After Allogeneic Stem Cell Transplantation for Pediatric Hematologic Malignancies","volume":"21","author":"Horn","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1601202","article-title":"Ipilimumab for Patients With Relapse After Allogeneic Transplantation","volume":"375","author":"Davids","year":"2016","journal-title":"N Engl J Med"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019004710","article-title":"A Multicenter Phase 1 Study of Nivolumab for Relapsed Hematologic Malignancies After Allogeneic Transplantation","volume":"135","author":"Davids","year":"2020","journal-title":"Blood"},{"key":"B103","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1182\/blood-2019-126271","article-title":"The First-in-Class Anti-CD47 Antibody Magrolimab (5F9) in Combination With Azacitidine Is Effective in MDS and AML Patients: Ongoing Phase 1b Results","volume":"134","author":"Sallman","year":"2019","journal-title":"Blood"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020002512","article-title":"TP53 Abnormalities Correlate With Immune Infiltration and Associate With Response to Flotetuzumab Immunotherapy in AML","volume":"4","author":"Vadakekolathu","year":"2020","journal-title":"Blood Adv"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in Children and Young Adults With B-Cell Lymphoblastic Leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-0719-y","article-title":"Remission of Acute Myeloid Leukemia With T(8;21) Following CD19 CAR T-Cells","volume":"34","author":"Danylesko","year":"2020","journal-title":"Leukemia"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-018-0423-y","article-title":"Successful Treatment of Two Relapsed\/Refractory T(8;21) Acute Myeloid Leukemia Patients by CD19-Directed Chimeric Antigen Receptor T Cells","volume":"54","author":"Qu","year":"2019","journal-title":"Bone Marrow Transplant"},{"key":"B108","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1182\/blood-2021-152692","article-title":"Phase 1\/1b Safety Study of Prgn-3006 Ultracar-T in Patients With Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndromes","volume":"138","author":"Sallman","year":"2021","journal-title":"Blood"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-021-01092-4","article-title":"CD38-Directed CAR-T Cell Therapy: A Novel Immunotherapy Strategy for Relapsed Acute Myeloid Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation","volume":"14","author":"Cui","year":"2021","journal-title":"J Hematol Oncol"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-4543","article-title":"Anti-CLL1 Chimeric Antigen Receptor T-Cell Therapy in Children With Relapsed\/Refractory Acute Myeloid Leukemia","volume":"27","author":"Zhang","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019002779","article-title":"Bispecific and Split CAR T Cells Targeting CD13 and TIM3 Eradicate Acute Myeloid Leukemia","volume":"135","author":"He","year":"2020","journal-title":"Blood"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.70.7059","article-title":"KIR3DL1\/HLA-B Subtypes Govern Acute Myelogenous Leukemia Relapse After Hematopoietic Cell Transplantation","volume":"35","author":"Boudreau","year":"2017","journal-title":"J Clin Oncol"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2015.12.028","article-title":"Phase II Study of Haploidentical Natural Killer Cell Infusion for Treatment of Relapsed or Persistent Myeloid Malignancies Following Allogeneic Hematopoietic Cell Transplantation","volume":"22","author":"Shaffer","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-021-01349-4","article-title":"Decrease Post-Transplant Relapse Using Donor-Derived Expanded NK-Cells","author":"Ciurea","year":"2021","journal-title":"Leukemia"},{"key":"B115","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1111\/bjh.17426","article-title":"Second Allogeneic Haematopoietic Cell Transplantation Using HLA-Matched Unrelated Versus T-Cell Replete Haploidentical Donor and Survival in Relapsed Acute Myeloid Leukaemia","volume":"193","author":"Kharfan-Dabaja","year":"2021","journal-title":"Br J Haematol"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-019-0251-3","article-title":"Donor Selection for a Second Allogeneic Stem Cell Transplantation in AML Patients Relapsing After a First Transplant: A Study of the Acute Leukemia Working Party of EBMT","volume":"9","author":"Shimoni","year":"2019","journal-title":"Blood Cancer J"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2017.07.014","article-title":"Major Histocompatibility Mismatch and Donor Choice for Second Allogeneic Bone Marrow Transplantation","volume":"23","author":"Imus","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.2091","article-title":"Association of Second Allogeneic Hematopoietic Cell Transplant vs Donor Lymphocyte Infusion With Overall Survival in Patients With Acute Myeloid Leukemia Relapse","volume":"4","author":"Kharfan-Dabaja","year":"2018","journal-title":"JAMA Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2021.812207\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,16]],"date-time":"2021-12-16T05:24:27Z","timestamp":1639632267000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2021.812207\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,16]]},"references-count":118,"alternative-id":["10.3389\/fonc.2021.812207"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2021.812207","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,16]]},"article-number":"812207"}}